Acumen Pharmaceuticals Inc’s filing revealed that its President and CEO OConnell Daniel Joseph unloaded Company’s shares for reported $52753.0 on Jan 19 ’24. In the deal valued at $3.47 per share,15,200 shares were sold. As a result of this transaction, OConnell Daniel Joseph now holds 502,485 shares worth roughly $1.76 million.
Then, Meisner Derek M sold 8,933 shares, generating $31,048 in total proceeds. Upon selling the shares at $3.48, the Chief Legal Officer & Corp Sec now owns 108,867 shares.
Before that, Zuga Matt sold 4,242 shares. Acumen Pharmaceuticals Inc shares valued at $15,717 were divested by the CFO & Chief Business Officer at a price of $3.71 per share. As a result of the transaction, Zuga Matt now holds 211,445 shares, worth roughly $0.74 million.
Deutsche Bank initiated its Acumen Pharmaceuticals Inc [ABOS] rating to a Buy in a research note published on December 12, 2023; the price target was $8. Cantor Fitzgerald began covering ABOS with “an Overweight” recommendation on May 18, 2023. BTIG Research started covering the stock on July 15, 2022. It rated ABOS as “a Buy”.
Price Performance Review of ABOS
On Tuesday, Acumen Pharmaceuticals Inc [NASDAQ:ABOS] saw its stock fall -0.85% to $3.50. Over the last five days, the stock has lost -8.85%. Acumen Pharmaceuticals Inc shares have fallen nearly -8.85% since the year began. Nevertheless, the stocks have fallen -6.42% over the past one year. While a 52-week high of $11.31 was reached on 03/04/24, a 52-week low of $1.81 was recorded on 02/02/24. SMA at 50 days reached $3.83, while 200 days put it at $4.28. A total of 0.22 million shares were traded, compared to the trading of 0.18 million shares in the previous session.
Levels Of Support And Resistance For ABOS Stock
The 24-hour chart illustrates a support level at 3.40, which if violated will result in even more drops to 3.30. On the upside, there is a resistance level at 3.60. A further resistance level may holdings at 3.70. The Relative Strength Index (RSI) on the 14-day chart is 38.90, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.24, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 88.64%. Stochastics %K at 24.62% indicates the stock is a holding.
The most recent change occurred on June 30, 2022 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $15 price target.
